FDA Compliance for Peptide Therapy and BPC 157 Holt Law The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and commercialization When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions FDA mulls compounding for peptides previously flagged over safety risks BioSpace